188 jili tv
188 jili tv
Veeva Announces Fiscal 2025 Third Quarter ResultsPeter Dutton will use a private Coalition meeting to calm MPs fearful that Labor’s teen social media ban is a Trojan Horse for government control of the internet, ahead of a sitting week in which the major parties plan to ram the legislation through parliament. On Friday Coalition MPs were called to a Monday morning gathering in Canberra, party sources said, where Dutton and communications spokesman David Coleman planned to field questions about Labor’s proposed law to ban children under 16 from platforms such as TikTok and Instagram. Opposition Leader Peter Dutton and communications spokesman David Coleman will face concerned MPs. Credit: Louise Kennerley Right-wing Coalition senators Matt Canavan and Alex Antic have been sharply critical of the bill’s potential to require Australians to give tech giants their IDs and the power it would give the eSafety Commission, which is a federal agency that will be charged with overseeing the ban. But doubts about the bill, which was only released last week, have expanded from the pair to more mainstream Coalition MPs, setting up the meeting as a test of the opposition leader’s authority after he hauled his party room into line on abortion earlier this month. On Sunday night, the MPs were informed Monday’s meeting was cancelled, with the conversation to take place on Tuesday as part of the Coalition’s party room meeting. The Coalition leadership remains confident of overwhelming support for the bill inside the party, according to several opposition sources speaking anonymously about internal dynamics. Dutton, whose office declined to comment, plans to hear out his concerned colleagues but ultimately expects the party to back the bill, allowing it to pass parliament this week. The opposition rode a wave of conservative and libertarian campaigning against Labor’s misinformation bill in recent months before the government dropped its plan to crack down on falsehoods online on Sunday. Some of the groups and people behind that campaign, including One Nation, the Libertarian Party and former Coalition MPs George Christensen and Craig Kelly, have launched an email crusade about the social media age barrier that has resulted in complaints flooding into MPs inboxes. They endorse the view of X owner Elon Musk, who wrote on the platform last month that the ban “seems like a backdoor way to control access to the internet by all Australians” because it could require users to prove their identities before accessing major online services. Communications Minister Michelle Rowland was asked about the need to hand over ID in a Labor caucus meeting last week and said her laws would not force people to give ID documents to social media giants, dismissing the prospect as a right-wing scare campaign. However, the government has not announced the technology that would be used to prove a user’s age. ‘A red flag’ LNP MP Garth Hamilton said Labor had rushed the legislation and sent mixed signals about details such as which platforms would be included. The Wiggles successfully lobbied to allow YouTube to remain while Snapchat will be banned, though both apps now also have a TikTok-style feed of clips. “The tests for this bill are that it should not be a proxy for digital ID [to be required to access the internet] and that it actually responds to parents’ needs,” Hamilton said.“I fully agree with Peter Dutton’s concerns about the impacts of social media, and they are long-held. But Labor has had a long time to get details right [and] the utter confusion on the detail is a red flag.” Loading Coleman, who first proposed a teen ban in an April interview with this masthead at a time when Labor opposed such a change , told opposition MPs last week that the government could use a “double-blind tokenised approach” suggested by the eSafety Commission last year. That would allow a third party to verify a user’s age on a social media platform without revealing the identity information used to do so, while another option could force companies that operate app stores, such as Google and Apple, to take on the role. Labor announced the ban early this month after years of claims that social media was harming children’s mental health, much of which is disputed by the technology giants, and argued that it would bolster parents’ ability to reject pestering from kids to go online. But detractors including Ben Thompson, the boss of major Australian tech firm Employment Hero, said on X that bill would make it harder for children with special needs to make friends online. “Not to mention that it’s a Trojan Horse for digital ID and further censorship,” he said. On Sunday, Greens communications spokeswoman Sarah Hanson-Young called advocates for the ban well-intentioned, but said the bill was rushed compared to the government’s halting approach to gambling reform. “The government and the opposition are ramming through a ban on social media that was introduced on Thursday,” she said on ABC’s Insiders . “We’ve got a joke of a Senate inquiry for three days tomorrow. But they can’t do gambling ... Talk about priorities.” Cut through the noise of federal politics with news, views and expert analysis. Subscribers can sign up to our weekly Inside Politics newsletter . Save Log in , register or subscribe to save articles for later. License this article Social media Peter Dutton Anthony Albanese Paul Sakkal is federal political correspondent for The Age and Sydney Morning Herald who previously covered Victorian politics and has won two Walkley awards. Connect via Twitter . Most Viewed in Politics Loading
The largest credit union credit card issuer in Canada is partnering with digital identity verification company . Collabria Financial Services serves more than 98 percent of credit unions across Canada, and by integrating Trulioo’s verification capabilities the company is hoping to deliver fast, compliant and automated onboarding. It’s expected that Collabria will allow the full automation of Trulioo’s Know Your Business review in addition to its Know Your Client process. “The partnership with Trulioo marks a pivotal step forward in enhancing our security measures, while delivering a more streamlined, customer centric process,” said Collabria CEO Jean-Marc Handifeld. Trulioo CEO Steve Munford commented: “We are proud to partner with Collabria to deliver streamlined identity verification solutions for their cardholders.” Trulioo has been seeking to expand its business in the Asia-Pacific region, which is where some of its executives have been attending events recently. Asia is of course host to some major ongoing digital transformation with numerous countries, especially in Southeast Asia, having built or in the process of building national digital identity systems. In addition, financial institutions, banks and card companies – for example Mastercard – are part of the digital transformation. Interviewed by at Singapore Fintech Festival 2024, Trulioo’s APAC director of operations Ivan Yang said that many of the company’s North American and European clients are expanding into Southeast Asia while APAC companies are seeking to scale internationally. In addition, Trulioo is experiencing strong demand within the payments, remittance and marketplace sectors, powered by APAC’s digital transformation. Yang revealed that in China and Australia, where they have strong national ID systems, Trulioo works with government agencies on streamlining verification processes; but that navigating the diverse regulatory environment across APAC means local partnerships can make a big difference. Yang singled out Singapore’s implementation of SingPass as a benchmark for digital identity standards, which has influenced Trulioo’s approach to verification across APAC. Meanwhile, Trulioo chief technology officer Hal Lonas pointed to its partnerships, like the ones it has with Airwallex and Mastercard, as strengthening its platform’s resilience and allowing further technological refinements. Trulioo chief product officer Zac Cohen was interviewed at Money 20/20 USA and highlighted the “nuance” in which enterprises operate, when considering the different demographics they serve, whether that’s the U.S. or Japan or Latin America, he said by way of example. Cohen was prompted on burgeoning transactional volume, and deferred to growing “digital participation” in the economy and emphasized equal access and a “level playing field” for the digital ecosystem. On the regulatory landscape Cohen referred to “stricter measures” around data privacy and what organizations can do with the data they process. In addition, there’s growing transparency for users to see how they’re data is being used; a greater consolidation in regulations that was begun by GDPR. Asked about what trends he’s watching in his sector as we approach the new year, Cohen replied that one of the big trends for Trulioo is the “different ways people want to identify themselves” – and went on to mention electronic IDs in Europe, mobile driver’s licenses in the U.S., and lastly the trend of “fraud intelligence.” You can watch the full interview . | | | | | | |
Jailed PKK Leader open to working with Turkey, DEM SaysBEREA, Ohio (AP) — The Cleveland Browns have again restructured quarterback Deshaun Watson's massive contract to create salary-cap space and give them future flexibility, a person familiar with the move told The Associated Press on Friday. Watson has been limited to just 19 games in three seasons because of an NFL suspension and injuries with the Browns, who signed him to a five-year, $230 million fully guaranteed contract in 2022. The restructuring allows the team to spread out the salary-cap hit after the 2026 season, said the person, who spoke on condition of anonymity because the team does not disclose contract specifics. The 29-year-old Watson has two years remaining on his contract with an average of $46 million a year. The move to restructure his deal will not preclude the Browns from adding talent at the quarterback position in 2025, the person said. Watson played in only seven games this season before suffering a ruptured Achilles tendon. He's 9-10 as a starter with Cleveland. The Browns (3-12) have been a major disappointment this season after making it to the playoffs a year ago behind Joe Flacco, who was signed as a free agent after Watson suffered a season-ending shoulder injury. Watson had surgery in October and is expected to make a full recovery. While the team hasn't disclosed its plans at quarterback, it's assumed Watson will be in the mix to be the starter next season. It's also possible the Browns will draft a quarterback in the first round. The team hasn't had a first-round pick the past three years after trading three to the Houston Texans to acquire Watson, who was once considered one of the league's elite QBs. Watson's disappointing tenure has been a sore spot with Cleveland fans, who had hoped the team had finally resolved its interminable QB issues when they signed the three-time Pro Bowler three years ago. But it hasn't worked out, and the major investment in Watson and the salary-cap ramifications of his contract — the largest fully guaranteed deal in league history — have made it difficult for the Browns to upgrade their roster. Watson has shown flashes of being a competent starting quarterback, but there have been just as many moments in which he's looked hesitant in the pocket or unable to connect with receivers down field. Watson was suspended for the first 11 games of his first season in Cleveland after an independent arbiter ruled he violated the conduct policy after he was accused by more than two dozen women of sexual misconduct during massage therapy sessions. AP NFL: https://apnews.com/hub/NFL
HARRY Derbudge might be entering 2025 as a single man, after his latest romance may already have ended. The Only Way Is Essex star Harry Derbidge recently announced he was loved up, after suffering a rollercoaster of heartbreak earlier this year. Loved up with tattooed Aussie hairdresser Jam Gaud, Harry was said to be "really happy" with the new relationship but he's now dropped a hint he's single meaning it might not have been perfect. The couple had shared selfies on social media, making their relationship Instagram official but Harry has now appeared to have deleted all trace of Jam across his personal social media accounts. Adding more fuel to the fire that he could now be single, Harry also posted a cryptic Instagram clue. Answering a fan's Q&A where he was asked about his happiest moment in 2024, Harry shared a snap of himself alongside some of his closest friends and co-stars. More on Harry Derbidge He wrote across the picture: "Is having good people around me, friends and family that will always be there for you. "A man may not show me love but I promise you I feel loved by my friends and family and no one will take that away." Earlier in December, it was revealed that Harry and Jam were happily coupled up and the Aussie had even met Harry's family. A source told us: "Harry and Jam have been dating for a few months, he's really happy and he's got his family approval, including his cousin Amy Childs . Most read in Celebrity "His Towie co-stars are chuffed that he's found love again." They added: "Harry is looking forward to the future after the whole Towie saga and split from Joe and wants to put that behind him. "He has healed now and is looking forward to what the future holds." Harry suffered heartbreak and betrayal earlier this year when his ex Joe Blackman ended their engagement, and then began a romance with TOWIE co-star Junaid Ahmed. The drama has recently played out on the most recent series of the ITVBe show. At the end of the series Junaid was seen in tears as he called best mate Dani Imbert to tell her it was over. Despite that, the pair are still very much together and were spotted together on a boozy night out in November. Harry Derbidge's love life has been a whirlwind 2021 - Harry dated and was engaged to Dean Rowland, before the relationship ended in October 2021 2022 - In February 2022, just before Valentine's Day, Harry went Instagram official with a new man named Jackson Lonergan. They dated for a while and Jackson even appeared on TOWIE before the romance fizzled out 2023 - Harry and Joe Blackman begin dating, with the relationship playing out on screen on TOWIE. However it doesn't all go smoothly for the pair 2024 - Harry and Joe struggled and found they were having issues during their time on a cast trip to Cyprus, later splitting when they returned to Essex. Shortly after Harry is left feeling betrayed as his best friend Junaid Ahmed begins dating Joe 2024 - Harry is linked to Aussie hairdresser Jam Gaud, with the pair sharing pictures on social media together and said to be enjoying a new romancePRINCETON, N.J.--(BUSINESS WIRE)--Dec 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ENVISION trial’s efficacy and safety results at the Society of Urologic Oncology (SUO) annual meeting in Dallas, TX. These results, published online in the Journal of Urology in October, demonstrate that treatment with investigational therapy UGN-102, a mitomycin-based intravesical solution, resulted in a high and clinically meaningful complete response rate that was durable in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). "Finding options for patients with recurrent low-grade bladder cancer continues to be a major unmet need,” says Max Kates, R. Christian B. Evensen Professor and an Associate Professor of Urology and Oncology, and Director, Division of Urologic Oncology at the Brady Urological Institute at Johns Hopkins and ENVISION study investigator. “We are excited by the overall results of the ENVISION trial, especially the durability of response data, that support the potential of UGN-102 as a viable treatment option for these patients." In the ENVISION study, UGN-102 treatment showed an impressive 82.3% (95% CI: 75.9%, 87.1%) duration of response (DOR) at 12 months, according to the Kaplan-Meier estimate, in patients who achieved a complete response (CR) at 3 months following the initial treatment with UGN-102. The DOR at 15 months (n=43) and 18 months (n=9) remained robust, both at 80.9% (95% CI: 73.9%, 86.2%) according to the Kaplan-Meier estimates. These results build upon the trial’s positive primary endpoint, a 79.6% (95% CI: 73.9%, 84.5%) CR rate 3 months after the first instillation of UGN-102. The side effect profile of UGN-102 was consistent with previous clinical trials, further supporting its potential as a new treatment option for patients with LG-IR-NMIBC. "We are excited by the progress made in advancing UGN-102 as a potential treatment for LG-IR-NMIBC and securing a PDUFA goal date of June 13, 2025, from the FDA,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “The strong durability of response observed in the ENVISION study highlights UGN-102’s promising potential for patients. Given that many LG-IR-NMIBC patients are elderly and endure multiple surgeries under general anesthesia for their condition that impact their health and quality of life, there is an urgent need for alternative treatment options that can prolong recurrence-free periods and enhance patient outcomes." The most common treatment-emergent adverse events (TEAEs) in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention. TEAEs were typically mild-to-moderate in severity and resolved or resolving. The ENVISION trial demonstrated a similar safety profile to that observed in other studies of UGN-102. About UGN-102 UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel ® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to treat tumors by enabling longer exposure of bladder tissue to mitomycin. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. UroGen completed the NDA submission for UGN-102 in August, ahead of schedule. The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025. About Non-Muscle Invasive Bladder Cancer (NMIBC) In the U.S., bladder cancer is the second most common urologic cancer in men. LG-IR-NMIBC represents approximately 22,000 newly diagnosed bladder cancer patients each year and an estimated 60,000 recurrences annually among patients diagnosed from previous years. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include trans-urethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. LG-IR-NMIBC is characterized by early or frequent recurrences, multiple tumors, or a solitary tumor larger than three centimeters. About ENVISION The Phase 3 ENVISION trial is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 (mitomycin) for intravesical solution as a therapy for patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of UGN-102. The primary endpoint evaluated the CR rate at the three-month assessment after the first instillation, and the key secondary endpoint evaluated durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at www.clinicaltrials.gov (NCT05243550). About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 as the first FDA-approved treatment for LG-IR-NMIBC; the long-term results in the ENVISION trial supporting the potential of UGN-102 as a viable treatment option for LG-IR NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential benefits to patients and opportunities for UGN-102, if approved; statements related to the PDUFA goal date for UGN-102 and the potential approval and timing thereof; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: even though the NDA for UGN-102 has been accepted for filing by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-102 on the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024 (which is available at www.sec.gov ), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. View source version on businesswire.com : https://www.businesswire.com/news/home/20241205065029/en/ CONTACT: INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@UroGen.com 609-460-3588 ext. 1093MEDIA CONTACT: Cindy Romano Director, Communications cindy.romano@urogen.com 609-460-3583 ext. 1083 KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: ONCOLOGY FDA HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: UroGen Pharma Ltd. Copyright Business Wire 2024. PUB: 12/05/2024 03:15 PM/DISC: 12/05/2024 03:17 PM http://www.businesswire.com/news/home/20241205065029/enTrump attacks 'dumbest' 2023 debt limit extensionAP Trending SummaryBrief at 5:42 p.m. EST
Luke Humphries defeats Luke Littler to retain Players Championship Finals title
NORTH BAY, Ont. — Dalyn Wakely scored twice as the Barrie Colts topped the North Bay Battalion 3-1 in Ontario Hockey League play on Sunday. Zach Wigle had the other goal for Barrie. Briir Long replied for North Bay. PETERBOROUGH, Ont. — Will Gerrior scored the game-winning goal at 19:49 of the third period as the 67's edged the Petes. It was his second goal of the game. Cooper Foster, Henry Mews and Chris Barlas added singles in Ottawa's victory. SAULT STE. MARIE, Ont. — Cole Davis had a hat trick as the Windsor Spitfires topped the Sault Ste. Marie Greyhounds. Liam Greentree scored twice for the Spitfires. SUDBURY, Ont. — Adrian Misaljevic's overtime winner gave the Rangers a victory over the Wolves. Luke Ellinas and Haeden Ellis scored in regulation for Kitchener. FLINT, Mich. — Noah Aboflan had a goal and an assist as the London Knights downed Flint Firebirds. PJ Fagan II, Henry Brzustewicz and Andoni Fimis also scored for London. SAGINAW, Mich. — Carson Harmer scored three goals as the Saginaw Spirit defeated the Niagara IceDogs. Calem Mangone added two goals while Ethan Hay tallied once for Saginaw. OSHAWA, Ont. — Luca Marrelli had a goal and an assist as the Oshawa Generals downed the Kingston Frontenacs. Owen Griffin, Lauri Sinivuori and Colby Barlow also scored for Oshawa. This roundup was generated automatically with a CP-developed application. This report by The Canadian Press was first published Dec. 29, 2024. The Canadian Press
TEXAS A&M-CORPUS CHRISTI 82, LE MOYNE 61Reports: Bill Belichick interviews for North Carolina job
Luke Humphries defeats Luke Littler to retain Players Championship Finals titleTowson football wins 3rd straight, hopes for FCS playoffs bid | ROUNDUP
Anderson to Starc: Five up for grabs in IPL player auction
One Of The Unhealthiest Beef Stock Brands Is Already In Your Pantry
In a significant diplomatic move, U.S. President-elect Donald Trump announced on Thursday that he has selected former Senator David Perdue to serve as the ambassador to China. Trump's decision was revealed via a post on his social media platform Truth Social. Trump underscored the importance of Perdue's role, stating that he will be instrumental in implementing a strategy aimed at maintaining peace in the region and fostering a productive working relationship with Chinese leadership. With his inauguration set for January 20, 2025, Trump reiterated his commitment to strengthening U.S.-China relations through strategic appointments and policy measures. The President-elect also reiterated his intended trade policy stance, threatening a 10% tariff on Chinese goods unless China makes efforts to curb fentanyl trafficking. During his campaign, Trump warned of even higher tariffs, potentially exceeding 60%, on Chinese imports if necessary changes are not met by Beijing. (With inputs from agencies.)
188 jili tv
Veeva Announces Fiscal 2025 Third Quarter ResultsPeter Dutton will use a private Coalition meeting to calm MPs fearful that Labor’s teen social media ban is a Trojan Horse for government control of the internet, ahead of a sitting week in which the major parties plan to ram the legislation through parliament. On Friday Coalition MPs were called to a Monday morning gathering in Canberra, party sources said, where Dutton and communications spokesman David Coleman planned to field questions about Labor’s proposed law to ban children under 16 from platforms such as TikTok and Instagram. Opposition Leader Peter Dutton and communications spokesman David Coleman will face concerned MPs. Credit: Louise Kennerley Right-wing Coalition senators Matt Canavan and Alex Antic have been sharply critical of the bill’s potential to require Australians to give tech giants their IDs and the power it would give the eSafety Commission, which is a federal agency that will be charged with overseeing the ban. But doubts about the bill, which was only released last week, have expanded from the pair to more mainstream Coalition MPs, setting up the meeting as a test of the opposition leader’s authority after he hauled his party room into line on abortion earlier this month. On Sunday night, the MPs were informed Monday’s meeting was cancelled, with the conversation to take place on Tuesday as part of the Coalition’s party room meeting. The Coalition leadership remains confident of overwhelming support for the bill inside the party, according to several opposition sources speaking anonymously about internal dynamics. Dutton, whose office declined to comment, plans to hear out his concerned colleagues but ultimately expects the party to back the bill, allowing it to pass parliament this week. The opposition rode a wave of conservative and libertarian campaigning against Labor’s misinformation bill in recent months before the government dropped its plan to crack down on falsehoods online on Sunday. Some of the groups and people behind that campaign, including One Nation, the Libertarian Party and former Coalition MPs George Christensen and Craig Kelly, have launched an email crusade about the social media age barrier that has resulted in complaints flooding into MPs inboxes. They endorse the view of X owner Elon Musk, who wrote on the platform last month that the ban “seems like a backdoor way to control access to the internet by all Australians” because it could require users to prove their identities before accessing major online services. Communications Minister Michelle Rowland was asked about the need to hand over ID in a Labor caucus meeting last week and said her laws would not force people to give ID documents to social media giants, dismissing the prospect as a right-wing scare campaign. However, the government has not announced the technology that would be used to prove a user’s age. ‘A red flag’ LNP MP Garth Hamilton said Labor had rushed the legislation and sent mixed signals about details such as which platforms would be included. The Wiggles successfully lobbied to allow YouTube to remain while Snapchat will be banned, though both apps now also have a TikTok-style feed of clips. “The tests for this bill are that it should not be a proxy for digital ID [to be required to access the internet] and that it actually responds to parents’ needs,” Hamilton said.“I fully agree with Peter Dutton’s concerns about the impacts of social media, and they are long-held. But Labor has had a long time to get details right [and] the utter confusion on the detail is a red flag.” Loading Coleman, who first proposed a teen ban in an April interview with this masthead at a time when Labor opposed such a change , told opposition MPs last week that the government could use a “double-blind tokenised approach” suggested by the eSafety Commission last year. That would allow a third party to verify a user’s age on a social media platform without revealing the identity information used to do so, while another option could force companies that operate app stores, such as Google and Apple, to take on the role. Labor announced the ban early this month after years of claims that social media was harming children’s mental health, much of which is disputed by the technology giants, and argued that it would bolster parents’ ability to reject pestering from kids to go online. But detractors including Ben Thompson, the boss of major Australian tech firm Employment Hero, said on X that bill would make it harder for children with special needs to make friends online. “Not to mention that it’s a Trojan Horse for digital ID and further censorship,” he said. On Sunday, Greens communications spokeswoman Sarah Hanson-Young called advocates for the ban well-intentioned, but said the bill was rushed compared to the government’s halting approach to gambling reform. “The government and the opposition are ramming through a ban on social media that was introduced on Thursday,” she said on ABC’s Insiders . “We’ve got a joke of a Senate inquiry for three days tomorrow. But they can’t do gambling ... Talk about priorities.” Cut through the noise of federal politics with news, views and expert analysis. Subscribers can sign up to our weekly Inside Politics newsletter . Save Log in , register or subscribe to save articles for later. License this article Social media Peter Dutton Anthony Albanese Paul Sakkal is federal political correspondent for The Age and Sydney Morning Herald who previously covered Victorian politics and has won two Walkley awards. Connect via Twitter . Most Viewed in Politics Loading
The largest credit union credit card issuer in Canada is partnering with digital identity verification company . Collabria Financial Services serves more than 98 percent of credit unions across Canada, and by integrating Trulioo’s verification capabilities the company is hoping to deliver fast, compliant and automated onboarding. It’s expected that Collabria will allow the full automation of Trulioo’s Know Your Business review in addition to its Know Your Client process. “The partnership with Trulioo marks a pivotal step forward in enhancing our security measures, while delivering a more streamlined, customer centric process,” said Collabria CEO Jean-Marc Handifeld. Trulioo CEO Steve Munford commented: “We are proud to partner with Collabria to deliver streamlined identity verification solutions for their cardholders.” Trulioo has been seeking to expand its business in the Asia-Pacific region, which is where some of its executives have been attending events recently. Asia is of course host to some major ongoing digital transformation with numerous countries, especially in Southeast Asia, having built or in the process of building national digital identity systems. In addition, financial institutions, banks and card companies – for example Mastercard – are part of the digital transformation. Interviewed by at Singapore Fintech Festival 2024, Trulioo’s APAC director of operations Ivan Yang said that many of the company’s North American and European clients are expanding into Southeast Asia while APAC companies are seeking to scale internationally. In addition, Trulioo is experiencing strong demand within the payments, remittance and marketplace sectors, powered by APAC’s digital transformation. Yang revealed that in China and Australia, where they have strong national ID systems, Trulioo works with government agencies on streamlining verification processes; but that navigating the diverse regulatory environment across APAC means local partnerships can make a big difference. Yang singled out Singapore’s implementation of SingPass as a benchmark for digital identity standards, which has influenced Trulioo’s approach to verification across APAC. Meanwhile, Trulioo chief technology officer Hal Lonas pointed to its partnerships, like the ones it has with Airwallex and Mastercard, as strengthening its platform’s resilience and allowing further technological refinements. Trulioo chief product officer Zac Cohen was interviewed at Money 20/20 USA and highlighted the “nuance” in which enterprises operate, when considering the different demographics they serve, whether that’s the U.S. or Japan or Latin America, he said by way of example. Cohen was prompted on burgeoning transactional volume, and deferred to growing “digital participation” in the economy and emphasized equal access and a “level playing field” for the digital ecosystem. On the regulatory landscape Cohen referred to “stricter measures” around data privacy and what organizations can do with the data they process. In addition, there’s growing transparency for users to see how they’re data is being used; a greater consolidation in regulations that was begun by GDPR. Asked about what trends he’s watching in his sector as we approach the new year, Cohen replied that one of the big trends for Trulioo is the “different ways people want to identify themselves” – and went on to mention electronic IDs in Europe, mobile driver’s licenses in the U.S., and lastly the trend of “fraud intelligence.” You can watch the full interview . | | | | | | |
Jailed PKK Leader open to working with Turkey, DEM SaysBEREA, Ohio (AP) — The Cleveland Browns have again restructured quarterback Deshaun Watson's massive contract to create salary-cap space and give them future flexibility, a person familiar with the move told The Associated Press on Friday. Watson has been limited to just 19 games in three seasons because of an NFL suspension and injuries with the Browns, who signed him to a five-year, $230 million fully guaranteed contract in 2022. The restructuring allows the team to spread out the salary-cap hit after the 2026 season, said the person, who spoke on condition of anonymity because the team does not disclose contract specifics. The 29-year-old Watson has two years remaining on his contract with an average of $46 million a year. The move to restructure his deal will not preclude the Browns from adding talent at the quarterback position in 2025, the person said. Watson played in only seven games this season before suffering a ruptured Achilles tendon. He's 9-10 as a starter with Cleveland. The Browns (3-12) have been a major disappointment this season after making it to the playoffs a year ago behind Joe Flacco, who was signed as a free agent after Watson suffered a season-ending shoulder injury. Watson had surgery in October and is expected to make a full recovery. While the team hasn't disclosed its plans at quarterback, it's assumed Watson will be in the mix to be the starter next season. It's also possible the Browns will draft a quarterback in the first round. The team hasn't had a first-round pick the past three years after trading three to the Houston Texans to acquire Watson, who was once considered one of the league's elite QBs. Watson's disappointing tenure has been a sore spot with Cleveland fans, who had hoped the team had finally resolved its interminable QB issues when they signed the three-time Pro Bowler three years ago. But it hasn't worked out, and the major investment in Watson and the salary-cap ramifications of his contract — the largest fully guaranteed deal in league history — have made it difficult for the Browns to upgrade their roster. Watson has shown flashes of being a competent starting quarterback, but there have been just as many moments in which he's looked hesitant in the pocket or unable to connect with receivers down field. Watson was suspended for the first 11 games of his first season in Cleveland after an independent arbiter ruled he violated the conduct policy after he was accused by more than two dozen women of sexual misconduct during massage therapy sessions. AP NFL: https://apnews.com/hub/NFL
HARRY Derbudge might be entering 2025 as a single man, after his latest romance may already have ended. The Only Way Is Essex star Harry Derbidge recently announced he was loved up, after suffering a rollercoaster of heartbreak earlier this year. Loved up with tattooed Aussie hairdresser Jam Gaud, Harry was said to be "really happy" with the new relationship but he's now dropped a hint he's single meaning it might not have been perfect. The couple had shared selfies on social media, making their relationship Instagram official but Harry has now appeared to have deleted all trace of Jam across his personal social media accounts. Adding more fuel to the fire that he could now be single, Harry also posted a cryptic Instagram clue. Answering a fan's Q&A where he was asked about his happiest moment in 2024, Harry shared a snap of himself alongside some of his closest friends and co-stars. More on Harry Derbidge He wrote across the picture: "Is having good people around me, friends and family that will always be there for you. "A man may not show me love but I promise you I feel loved by my friends and family and no one will take that away." Earlier in December, it was revealed that Harry and Jam were happily coupled up and the Aussie had even met Harry's family. A source told us: "Harry and Jam have been dating for a few months, he's really happy and he's got his family approval, including his cousin Amy Childs . Most read in Celebrity "His Towie co-stars are chuffed that he's found love again." They added: "Harry is looking forward to the future after the whole Towie saga and split from Joe and wants to put that behind him. "He has healed now and is looking forward to what the future holds." Harry suffered heartbreak and betrayal earlier this year when his ex Joe Blackman ended their engagement, and then began a romance with TOWIE co-star Junaid Ahmed. The drama has recently played out on the most recent series of the ITVBe show. At the end of the series Junaid was seen in tears as he called best mate Dani Imbert to tell her it was over. Despite that, the pair are still very much together and were spotted together on a boozy night out in November. Harry Derbidge's love life has been a whirlwind 2021 - Harry dated and was engaged to Dean Rowland, before the relationship ended in October 2021 2022 - In February 2022, just before Valentine's Day, Harry went Instagram official with a new man named Jackson Lonergan. They dated for a while and Jackson even appeared on TOWIE before the romance fizzled out 2023 - Harry and Joe Blackman begin dating, with the relationship playing out on screen on TOWIE. However it doesn't all go smoothly for the pair 2024 - Harry and Joe struggled and found they were having issues during their time on a cast trip to Cyprus, later splitting when they returned to Essex. Shortly after Harry is left feeling betrayed as his best friend Junaid Ahmed begins dating Joe 2024 - Harry is linked to Aussie hairdresser Jam Gaud, with the pair sharing pictures on social media together and said to be enjoying a new romancePRINCETON, N.J.--(BUSINESS WIRE)--Dec 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ENVISION trial’s efficacy and safety results at the Society of Urologic Oncology (SUO) annual meeting in Dallas, TX. These results, published online in the Journal of Urology in October, demonstrate that treatment with investigational therapy UGN-102, a mitomycin-based intravesical solution, resulted in a high and clinically meaningful complete response rate that was durable in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). "Finding options for patients with recurrent low-grade bladder cancer continues to be a major unmet need,” says Max Kates, R. Christian B. Evensen Professor and an Associate Professor of Urology and Oncology, and Director, Division of Urologic Oncology at the Brady Urological Institute at Johns Hopkins and ENVISION study investigator. “We are excited by the overall results of the ENVISION trial, especially the durability of response data, that support the potential of UGN-102 as a viable treatment option for these patients." In the ENVISION study, UGN-102 treatment showed an impressive 82.3% (95% CI: 75.9%, 87.1%) duration of response (DOR) at 12 months, according to the Kaplan-Meier estimate, in patients who achieved a complete response (CR) at 3 months following the initial treatment with UGN-102. The DOR at 15 months (n=43) and 18 months (n=9) remained robust, both at 80.9% (95% CI: 73.9%, 86.2%) according to the Kaplan-Meier estimates. These results build upon the trial’s positive primary endpoint, a 79.6% (95% CI: 73.9%, 84.5%) CR rate 3 months after the first instillation of UGN-102. The side effect profile of UGN-102 was consistent with previous clinical trials, further supporting its potential as a new treatment option for patients with LG-IR-NMIBC. "We are excited by the progress made in advancing UGN-102 as a potential treatment for LG-IR-NMIBC and securing a PDUFA goal date of June 13, 2025, from the FDA,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “The strong durability of response observed in the ENVISION study highlights UGN-102’s promising potential for patients. Given that many LG-IR-NMIBC patients are elderly and endure multiple surgeries under general anesthesia for their condition that impact their health and quality of life, there is an urgent need for alternative treatment options that can prolong recurrence-free periods and enhance patient outcomes." The most common treatment-emergent adverse events (TEAEs) in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention. TEAEs were typically mild-to-moderate in severity and resolved or resolving. The ENVISION trial demonstrated a similar safety profile to that observed in other studies of UGN-102. About UGN-102 UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel ® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to treat tumors by enabling longer exposure of bladder tissue to mitomycin. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. UroGen completed the NDA submission for UGN-102 in August, ahead of schedule. The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025. About Non-Muscle Invasive Bladder Cancer (NMIBC) In the U.S., bladder cancer is the second most common urologic cancer in men. LG-IR-NMIBC represents approximately 22,000 newly diagnosed bladder cancer patients each year and an estimated 60,000 recurrences annually among patients diagnosed from previous years. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include trans-urethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. LG-IR-NMIBC is characterized by early or frequent recurrences, multiple tumors, or a solitary tumor larger than three centimeters. About ENVISION The Phase 3 ENVISION trial is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 (mitomycin) for intravesical solution as a therapy for patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of UGN-102. The primary endpoint evaluated the CR rate at the three-month assessment after the first instillation, and the key secondary endpoint evaluated durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at www.clinicaltrials.gov (NCT05243550). About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 as the first FDA-approved treatment for LG-IR-NMIBC; the long-term results in the ENVISION trial supporting the potential of UGN-102 as a viable treatment option for LG-IR NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential benefits to patients and opportunities for UGN-102, if approved; statements related to the PDUFA goal date for UGN-102 and the potential approval and timing thereof; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: even though the NDA for UGN-102 has been accepted for filing by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-102 on the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024 (which is available at www.sec.gov ), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. View source version on businesswire.com : https://www.businesswire.com/news/home/20241205065029/en/ CONTACT: INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@UroGen.com 609-460-3588 ext. 1093MEDIA CONTACT: Cindy Romano Director, Communications cindy.romano@urogen.com 609-460-3583 ext. 1083 KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: ONCOLOGY FDA HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: UroGen Pharma Ltd. Copyright Business Wire 2024. PUB: 12/05/2024 03:15 PM/DISC: 12/05/2024 03:17 PM http://www.businesswire.com/news/home/20241205065029/enTrump attacks 'dumbest' 2023 debt limit extensionAP Trending SummaryBrief at 5:42 p.m. EST
Luke Humphries defeats Luke Littler to retain Players Championship Finals title
NORTH BAY, Ont. — Dalyn Wakely scored twice as the Barrie Colts topped the North Bay Battalion 3-1 in Ontario Hockey League play on Sunday. Zach Wigle had the other goal for Barrie. Briir Long replied for North Bay. PETERBOROUGH, Ont. — Will Gerrior scored the game-winning goal at 19:49 of the third period as the 67's edged the Petes. It was his second goal of the game. Cooper Foster, Henry Mews and Chris Barlas added singles in Ottawa's victory. SAULT STE. MARIE, Ont. — Cole Davis had a hat trick as the Windsor Spitfires topped the Sault Ste. Marie Greyhounds. Liam Greentree scored twice for the Spitfires. SUDBURY, Ont. — Adrian Misaljevic's overtime winner gave the Rangers a victory over the Wolves. Luke Ellinas and Haeden Ellis scored in regulation for Kitchener. FLINT, Mich. — Noah Aboflan had a goal and an assist as the London Knights downed Flint Firebirds. PJ Fagan II, Henry Brzustewicz and Andoni Fimis also scored for London. SAGINAW, Mich. — Carson Harmer scored three goals as the Saginaw Spirit defeated the Niagara IceDogs. Calem Mangone added two goals while Ethan Hay tallied once for Saginaw. OSHAWA, Ont. — Luca Marrelli had a goal and an assist as the Oshawa Generals downed the Kingston Frontenacs. Owen Griffin, Lauri Sinivuori and Colby Barlow also scored for Oshawa. This roundup was generated automatically with a CP-developed application. This report by The Canadian Press was first published Dec. 29, 2024. The Canadian Press
TEXAS A&M-CORPUS CHRISTI 82, LE MOYNE 61Reports: Bill Belichick interviews for North Carolina job
Luke Humphries defeats Luke Littler to retain Players Championship Finals titleTowson football wins 3rd straight, hopes for FCS playoffs bid | ROUNDUP
Anderson to Starc: Five up for grabs in IPL player auction
One Of The Unhealthiest Beef Stock Brands Is Already In Your Pantry
In a significant diplomatic move, U.S. President-elect Donald Trump announced on Thursday that he has selected former Senator David Perdue to serve as the ambassador to China. Trump's decision was revealed via a post on his social media platform Truth Social. Trump underscored the importance of Perdue's role, stating that he will be instrumental in implementing a strategy aimed at maintaining peace in the region and fostering a productive working relationship with Chinese leadership. With his inauguration set for January 20, 2025, Trump reiterated his commitment to strengthening U.S.-China relations through strategic appointments and policy measures. The President-elect also reiterated his intended trade policy stance, threatening a 10% tariff on Chinese goods unless China makes efforts to curb fentanyl trafficking. During his campaign, Trump warned of even higher tariffs, potentially exceeding 60%, on Chinese imports if necessary changes are not met by Beijing. (With inputs from agencies.)
-
"> -
"> -
"> -
">
